PMID- 36905232
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230704
IS  - 1386-6346 (Print)
IS  - 1386-6346 (Linking)
VI  - 53
IP  - 7
DP  - 2023 Jul
TI  - Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB-4 
      index in metabolic-associated fatty liver disease.
PG  - 618-628
LID - 10.1111/hepr.13898 [doi]
AB  - BACKGROUND: The antidiabetic drugs sodium glucose cotransporter 2 inhibitors 
      (SGLT2is) and thiazolidinediones have beneficial effects on the liver dysfunction 
      of patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus 
      (T2DM). We aimed to determine the efficacy of these drugs for the treatment of 
      liver disease in patients with metabolic dysfunction-associated fatty liver 
      disease (MAFLD) and T2DM. METHODS: We undertook a retrospective study of 568 
      patients with MAFLD and T2DM. Of these, 210 were treating their T2DM with SGLT2is 
      (n = 95), 86 with pioglitazone (PIO), and 29 with both. The primary outcome was 
      the change in Fibrosis-4 (FIB-4) index between baseline and 96 weeks. RESULTS: At 
      96 weeks, the mean FIB-4 index had significantly decreased (from 
      1.79 +/- 1.10-1.56 +/- 0.75) in the SGLT2i group, but not in the PIO group. The 
      aspartate aminotransferase to platelet ratio index, serum aspartate and alanine 
      aminotransferase (ALT), hemoglobin A1c, and fasting blood sugar significantly 
      decreased in both groups (ALT: SGLT2i group, -17 +/- 3 IU/L; PIO group, 
      -14 +/- 3 IU/L). The bodyweight of the SGLT2i group decreased, but that of the PIO 
      group increased (-3.2 kg and +1.7 kg, respectively). When the participants were 
      allocated to two groups according to their baseline ALT (>30 IU/L), FIB-4 index 
      significantly decreased in both groups. In patients taking pioglitazone, the 
      addition of SGLT2i improved liver enzymes but not FIB-4 index for 96 weeks. 
      CONCLUSIONS: Treatment with SGLT2i causes a larger improvement in FIB-4 index 
      than PIO in patients with MAFLD over 96 weeks.
CI  - (c) 2023 Japan Society of Hepatology.
FAU - Mino, Masaaki
AU  - Mino M
AD  - Department of Gastroenterology and Hepatology, National Center for Global Health 
      and Medicine Kohnodai Hospital, Chiba, Japan.
FAU - Kakazu, Eiji
AU  - Kakazu E
AD  - Department of Gastroenterology and Hepatology, National Center for Global Health 
      and Medicine Kohnodai Hospital, Chiba, Japan.
AD  - Division of Gastroenterology, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
AD  - Department of Liver Diseases, The Research Center for Hepatitis and Immunology, 
      National Center for Global Health and Medicine, Tokyo, Japan.
FAU - Sano, Akitoshi
AU  - Sano A
AUID- ORCID: 0000-0002-8185-247X
AD  - Division of Gastroenterology, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Katsuyama, Hisayuki
AU  - Katsuyama H
AD  - Department of Diabetes, Endocrinology and Metabolism, National Center for Global 
      Health and Medicine Kohnodai Hospital, Chiba, Japan.
FAU - Hakoshima, Mariko
AU  - Hakoshima M
AD  - Department of Diabetes, Endocrinology and Metabolism, National Center for Global 
      Health and Medicine Kohnodai Hospital, Chiba, Japan.
FAU - Yanai, Hidekatsu
AU  - Yanai H
AD  - Department of Diabetes, Endocrinology and Metabolism, National Center for Global 
      Health and Medicine Kohnodai Hospital, Chiba, Japan.
FAU - Aoki, Yoshihiko
AU  - Aoki Y
AD  - Department of Gastroenterology and Hepatology, National Center for Global Health 
      and Medicine Kohnodai Hospital, Chiba, Japan.
FAU - Imamura, Masatoshi
AU  - Imamura M
AD  - Department of Gastroenterology and Hepatology, National Center for Global Health 
      and Medicine Kohnodai Hospital, Chiba, Japan.
FAU - Yamazoe, Taiji
AU  - Yamazoe T
AD  - Department of Liver Diseases, The Research Center for Hepatitis and Immunology, 
      National Center for Global Health and Medicine, Tokyo, Japan.
FAU - Mori, Taizo
AU  - Mori T
AD  - Department of Liver Diseases, The Research Center for Hepatitis and Immunology, 
      National Center for Global Health and Medicine, Tokyo, Japan.
FAU - Yoshio, Sachiyo
AU  - Yoshio S
AUID- ORCID: 0000-0001-7860-6916
AD  - Department of Liver Diseases, The Research Center for Hepatitis and Immunology, 
      National Center for Global Health and Medicine, Tokyo, Japan.
FAU - Inoue, Jun
AU  - Inoue J
AUID- ORCID: 0000-0003-1171-7835
AD  - Division of Gastroenterology, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Masamune, Atsushi
AU  - Masamune A
AD  - Division of Gastroenterology, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Kanto, Tatsuya
AU  - Kanto T
AD  - Department of Gastroenterology and Hepatology, National Center for Global Health 
      and Medicine Kohnodai Hospital, Chiba, Japan.
AD  - Department of Liver Diseases, The Research Center for Hepatitis and Immunology, 
      National Center for Global Health and Medicine, Tokyo, Japan.
LA  - eng
GR  - 20K08322/Ministry of Education, Culture, Sports, Science, and Technology/
GR  - JP22fk0210114/Ministry of Education, Culture, Sports, Science, and Technology/
GR  - 20A 3001/National Center for Global Health and Medicine/
PT  - Journal Article
DEP - 20230328
PL  - Netherlands
TA  - Hepatol Res
JT  - Hepatology research : the official journal of the Japan Society of Hepatology
JID - 9711801
OTO - NOTNLM
OT  - Fibrosis-4 index
OT  - diabetes mellitus
OT  - fibrosis
OT  - metabolic dysfunction-associated fatty liver disease
OT  - sodium glucose cotransporter 2 inhibitor
EDAT- 2023/03/12 06:00
MHDA- 2023/03/12 06:01
CRDT- 2023/03/11 05:03
PHST- 2023/02/10 00:00 [revised]
PHST- 2022/10/17 00:00 [received]
PHST- 2023/03/04 00:00 [accepted]
PHST- 2023/03/12 06:01 [medline]
PHST- 2023/03/12 06:00 [pubmed]
PHST- 2023/03/11 05:03 [entrez]
AID - 10.1111/hepr.13898 [doi]
PST - ppublish
SO  - Hepatol Res. 2023 Jul;53(7):618-628. doi: 10.1111/hepr.13898. Epub 2023 Mar 28.